Background

The evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The epidemiology is well described in the western world but not in Asian countries like Malaysia.

Materials and methods

This retrospective national registry of MPN was conducted from year 2009 to 2015 in Malaysia.

Results

A total of 1010 patients were registered over a period of 5 years. The mean age was 54 years with male predominance. The ethnic distribution revealed that Chinese had a relatively high weighted incidence proportion (43.2%), followed by Indian (23.8%), Malay (15.8%) and other ethnic groups (17.2%). The types of MPN reported were 40.4% of ET (n = 408), 38.1% of PV (n = 385), 9.2% of PMF (n = 93), 3.1% of hypereosinophilic syndrome (HES) (n = 31) and 7.9% of unclassifiable MPN (MPN-U) (n = 80). Splenomegaly was only palpable clinically in 32.2% of patients. The positive JAK2 V617F mutation was present in 644 patients with 46.6% in PV, 36.0% in ET, 9.0% in PMF, and 7.4% in MPN-U, and had significantly lower haemoglobin (p < 0.001), haematocrit (p < 0.001) and white blood cells (WBC) (p < 0.001) than those with negative mutation. Significant differences in platelet and WBC count were detected in ethnic groups and MPN sub-types. There were more arterial thrombosis events seen in those with JAK2 V617F mutation as compared to venous thrombosis events (23.1% vs 4.4%). The bleeding rate was only 6.6%. Among the risk factors, previous thrombosis, old age (≥ 60 years) and hypertension were significantly correlated to positive JAK2 V617F mutation. The arterial thrombosis event is associated with higher presenting HB, HCT and PLT while the bleeding event is associated with lower presenting HB, HCT but higher PLT. The presence of JAK2 V617F mutation is associated with higher risk of arterial thrombosis.

Conclusion

Chinese ethnicity is associated with higher rates of MPN. The history of thrombosis, age ≥ 60 years and hypertension are risk factors that can be correlated to JAK2 V617F mutation. This study is instrumental for policy makers to ensure preventive strategies can be implemented in future.

1. Michiels, J. J., Berneman, Z., Schroyens, W., & De Raeve, H. (2015). Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: From Dameshek 1950 to Vainchenker 2005 and beyond. Acta Haematologica, 133(1), 36–51.
2. Hultcrantz, M., Kristinsson, S. Y., Andersson, T. M.-L., Landgren, O., Eloranta, S., Derolf, Å. R., et al. (2012). Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: A population-based study. Journal of Clinical Oncology, 30(24), 2995–3001.
3. Skoda, R. C., Duek, A., & Grisouard, J. (2015). Pathogenesis of myeloproliferative neoplasms. Experimental Hematology, 43(8), 599–608.
4. Spivak, J. L. (2017). Myeloproliferative neoplasms. The New England Journal of Medicine, 376(22), 2168–2181.
5. Ha, J.-S., Kim, Y.-K., Jung, S.-I., Jung, H.-R., & Chung, I.-S. (2012). Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Annals of Laboratory Medicine, 32(6), 385–391.
6. Titmarsh, G. J., Duncombe, A. S., McMullin, M. F., O’Rorke, M., Mesa, R., De Vocht, F., et al. (2014). How common are myeloproliferative neoplasms? A systematic review and meta-analysis. American Journal of Hematology, 89(6), 581–587.
7. Department of Statistics Malaysia. (2016). Population projections (revised), Malaysia, 2010–2040.
8. Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405.
9. Barbui, T., Thiele, J., Vannucchi, A., & Tefferi, A. (2015). Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer Journal, 5(8), e337.
10. Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., et al. (2007). JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England Journal of Medicine, 356(5), 459–468.
11. Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007). Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia, 21, 1960.
12. McMullin, M. F., Wilkins, B. S., & Harrison, C. N. (2016). Management of polycythaemia vera: A critical review of current data. British Journal of Haematology, 172(3), 337–349.
13. Barbui, T., Thiele, J., Vannucchi, A. M., & Tefferi, A. (2016). Myeloproliferative neoplasms: Morphology and clinical practice. American Journal of Hematology, 91(4), 430–433.
14. Lussana, F., Carobbio, A., Randi, M. L., Elena, C., Rumi, E., Finazzi, G., et al. (2014). A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. British Journal of Haematology, 167(4), 541–546.
15. Barbui, T., Thiele, J., Carobbio, A., Gisslinger, H., Finazzi, G., Rumi, E., et al. (2014). Masked polycythemia vera diagnosed according to WHO and BCSH classification. American Journal of Hematology, 89(2), 199–202.
16. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H. M., Barbui, T., Hanson, C. A., et al. (2007). Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood, 110(4), 1092–1097.
17. Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., et al. (2011). Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. Journal of Clinical Oncology, 29(23), 3179–3184.
18. Barosi, G. (2014). Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter? Best Practice & Research Clinical Haematology, 27(2), 129–140.
19. Zhang, X., Hu, T., Wu, Z., Kang, Z., Liu, W., & Guan, M. (2012). The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients. International Journal of Hematology, 96(5), 611–616.
20. Ohyashiki, J., Yoneta, M., Hisatomi, H., Iwabuchi, T., Umezu, T., & Ohyashiki, K. (2012). The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. BMC Medical Genetics, 13, 6.
21. Amy, V. J., & Nicholas, C. P. C. (2013). Inherited predisposition to myeloproliferative neoplasms. Therapeutic Advances in Hematology, 4(4), 237–253.
22. Barbui, T., Finazzi, G., & Falanga, A. (2013). Myeloproliferative neoplasms and thrombosis. Blood, 122(13), 2176–2184.
23. Falanga, A., & Marchetti, M. (2012). Thrombotic disease in the myeloproliferative neoplasms. Hematology: American Society of Hematology Education Program, 2012(1), 571–581.
24. Kaifie, A., Kirschner, M., Wolf, D., Maintz, C., Hänel, M., Gattermann, N., et al. (2016). Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms: Analysis from the German SAL-MPN-registry. Journal of Hematology & Oncology, 9(1), 18.
25. Kreher, S., Ochsenreither, S., Trappe, R. U., Pabinger, I., Bergmann, F., Petrides, P. E., et al. (2014). Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: Consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology, the Austrian Society of Hematology and Oncology and Society of Thrombosis and Haemostasis Research. Annals of Hematology, 93(12), 1953–1963.
26. Finazzi, G. (2004). A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia. Pathologie Biologie, 52(5), 285–288.
27. Marchetti, M., & Falanga, A. (2008). Leukocytosis, JAK2(V617F) mutation, and hemostasis in myeloproliferative disorders. Pathophysiology of Haemostasis and Thrombosis, 36, 148–159.
28. Martin, K. (2017). Risk factors for and management of MPN-associated bleeding and thrombosis. Current Hematologic Malignancy Reports, 12(5), 389–396.
29. Vannucchi, A. M., & Guglielmelli, P. (2013). JAK2 mutation-related disease and thrombosis. Seminars in Thrombosis and Hemostasis, 39(5), 496–506.
30. Barbui, T., Carobbio, A., Rambaldi, A., & Finazzi, G. (2009). Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: Is leukocytosis a causative factor? Blood, 114(4), 759–763.
31. Landolfi, R., Di Gennaro, L., Barbui, T., De Stefano, V., Finazzi, G., Marfisi, R., et al. (2007). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood, 109(6), 2446–2452.
32. Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., et al. (2011). Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: An international study of 891 patients. Blood, 117(22), 5857–5859.
33. Barbui, T., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., et al. (2012). Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia. Blood, 120(26), 5128–5133.
34. Campbell, P. J., MacLean, C., Beer, P. A., Buck, G., Wheatley, K., Kiladjian, J.-J., et al. (2012). Correlation of blood counts with vascular complications in essential thrombocythemia: Analysis of the prospective PT1 cohort. Blood, 120(7), 1409–1411.
35. Michiels, J. J., Berneman, Z., Schroyens, W., Finazzi, G., Budde, U., & van Vliet, H. H. D. M. (2006). The paradox of platelet activation and impaired function: Platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Seminars in Thrombosis and Hemostasis, 32(6), 589–604.
36. Srour, S. A., Devesa, S. S., Morton, L. M., Check, D. P., Curtis, R. E., Linet, M. S., et al. (2017). Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–2012. British Journal of Haematology, 174(3), 382–396.